- Home
- WEA vs YARW Comparison
WEA vs YARW Comparison
Compare WEA & YARW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WEA | YARW |
|---|---|---|
| Founded | 2002 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 125.4M | 114.6M |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | WEA | YARW |
|---|---|---|
| Price | $10.51 | $43.10 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 23.4K | 16.6K |
| Earning Date | 01-01-0001 | N/A |
| Dividend Yield | ★ 7.87% | N/A |
| EPS Growth | N/A | ★ 33.33 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.30 | $31.55 |
| 52 Week High | $11.44 | $44.28 |
Technical Indicators
Market Signals| Indicator | WEA | YARW |
|---|---|---|
| Relative Strength Index (RSI) | 52.27 | 83.16 |
| Support Level | $10.46 | N/A |
| Resistance Level | $10.72 | $44.28 |
| Average True Range (ATR) | 0.07 | 3.40 |
| MACD | 0.01 | 0.81 |
| Stochastic Oscillator | 89.58 | 91.00 |
Price Performance
Historical ComparisonAbout WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The fund invests in bonds of companies operating in different sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About YARW Yarrow Bioscience Inc. Common Stock
Yarrow Bioscience Inc is a clinical-stage biopharmaceutical company focused on developing biotherapeutics for autoimmune thyroid diseases. Its flagship product candidate, YB-101 (also known as GenSci098), is a humanized, monoclonal antibody targeting the thyroid-stimulating hormone receptor, which Yarrow plans to develop for the treatment of Graves' disease (GD) and potentially thyroid eye disease (TED). The company has one reportable segment relating to the research and development of its research programs, GD and TED.